Entero Healthcare Solutions Limited has released its Annual Report for the financial year 2025-26, alongside the Notice convening its 8th Annual General Meeting (AGM) scheduled for Wednesday, August 19, 2026, at 12:30 p.m. (IST), to be held through Video Conferencing (VC)/Other Audio Visual Means (OAVM). The filing was made with BSE Limited and National Stock Exchange of India Limited on July 27, 2026.

Key AGM Details

The following table summarises the schedule for the 8th AGM:

FY26 Financial Performance

FY26 marked a significant milestone in the company's evolution as an integrated healthcare supply chain platform. Consolidated revenue from operations grew 29.35% year-on-year to INR 65,912.12 million (FY25: INR 50,957.80 million), driven by 13.4% organic growth and 16% inorganic contribution. During the same period, the Indian Pharmaceutical Market grew by approximately 10%, reflecting continued market share gains by the company.

The following table presents the consolidated and standalone financial highlights for FY 2025-26:

Gross profit rose 39.91% year-on-year to INR 680.38 crore, with gross margins improving 78 basis points to 10.32%. EBITDA for the year stood at INR 265.96 crore, growing 55.03% year-on-year, with EBITDA margins improving 67 basis points to 4.03%. Profit After Tax (PAT) grew 35.75% to INR 145.84 crore (PAT margin: 2.21%), notwithstanding a one-time exceptional charge of INR 6.1 crore (net of tax) arising from the implementation of the new Labour Code.

Operating Cash Flow and Return Metrics

A notable highlight of FY26 was a meaningful improvement in operating cash flow, with OCF improving significantly from an outflow of INR 76.90 crore in FY25 to a net cash inflow from operations of approximately INR 96.20 crore in FY26, driven by better inventory management, tighter receivables control, and improved EBITDA margins.

Return metrics also strengthened considerably during the year:

Key Financial Ratios (Consolidated Basis)

The following table presents key financial ratios as disclosed in the Annual Report:

Operational Scale and Network

The company's platform as at FY26 serves over 105,300 retail pharmacy customers, 3,600+ hospital customers, and operates across 523 districts, supported by 136 warehouses and relationships with 3,300+ manufacturers. The portfolio spans 97,500+ SKUs handled. The company operates across 21 States & UTs with 6.29 lakh+ sq. ft. of warehousing space across 50 cities.

Strategic Acquisitions and MedTech Expansion

During FY26, the company completed seven strategic acquisitions across pharmaceutical distribution and the MedTech segment, contributing aggregate annualised revenue of over ₹1,000 crore. Three of these acquisitions were in the MedTech segment:

• Anand Chemiceutics Private Limited (51.51% stake) — leading IVD and MedTech distributor
• Ace Cardiopathy Solutions Private Limited (60% stake) — cardiovascular care MedTech distributor
• Bioaide Technologies Private Limited (80% stake) — focused on interventional cardiology, ENT, wound management, and neuropsychiatry

Additional acquisitions in pharmaceutical distribution included Ramson Medical Distributors Private Limited (70%), Sai RK Pharma Private Limited (70%), Well Wisher Pharma Private Limited (70%), and Anand Medilink Private Limited (80%). The MedTech vertical is expected to cross ₹1,000 crore in annualised revenue in FY27.

Dividend and Share Capital

The Board has not recommended any dividend for FY 2025-26 in order to conserve resources. During FY 2025-26, the paid-up equity share capital increased from Rs. 43,50,77,070/- to Rs. 43,51,09,370/-, pursuant to the allotment of 3,230 equity shares under the Entero Employees Stock Option Plan, 2023 (ESOP 2023). As on March 31, 2026, the company had 48 subsidiaries. India Ratings and Research affirmed the company's credit rating at 'IND A-' with a stable outlook during the year.

AGM Business and Director Appointments

The 8th AGM will consider ordinary business including adoption of audited financial statements for FY 2025-26 and re-appointment of Mr. Arun Sadhanandham (DIN: 08445197) as a Non-Executive Non-Independent Director, who retires by rotation. Special business includes approval of remuneration for Managing Director & CEO Mr. Prabhat Agrawal and Whole-time Director & COO Mr. Prem Sethi for their remaining tenures up to August 25, 2028, as well as re-appointment of Mr. Sujesh Vasudevan (DIN: 08240092) as Non-Executive Independent Director for a second term of 5 years (August 25, 2026 to August 24, 2031) and re-appointment of Ms. Sandhya Gadkari Sharma (DIN: 02005378) as Non-Executive Independent Director for a second term of 4 years (August 25, 2026 to August 24, 2030).

Entero Healthcare Solutions has scheduled its 8th Annual General Meeting (AGM) for Wednesday, August 19, 2026. The meeting is set to commence at 12:30 PM IST and will be conducted via Video Conferencing (VC) or Other Audio-Visual Means (OAVM), allowing shareholders to participate remotely without physical presence. This arrangement ensures broader accessibility for investors while adhering to regulatory guidelines for corporate governance during ongoing operational constraints.

The company issued the formal intimation on July 23, 2026, publishing newspaper advertisements in "Financial Express" (English) and "Satyajay Times" (Hindi). Sanu Kapoor, Vice President - Group General Counsel, Company Secretary & Compliance Officer, signed the communication to the listing compliance departments of both BSE Limited and National Stock Exchange of India Limited. The filing confirms that all necessary procedural steps for the remote AGM have been completed.

Meeting Details

Shareholders are advised to refer to the official meeting notice for agenda items and voting instructions. The company has made the relevant information available on its website at www.enterohealthcare.com , ensuring transparency and easy access to corporate documents. Investors should monitor the site for any further updates regarding e-voting timelines or technical requirements for joining the virtual session.

Corporate Governance Update

The decision to hold the AGM remotely reflects the company's commitment to maintaining continuous engagement with its investor base. By utilizing VC/OAVM facilities, Entero Healthcare Solutions ensures that geographical barriers do not hinder shareholder participation. The compliance officer’s signature on the exchange filing validates the authenticity of the announcement and aligns with SEBI regulations concerning general meetings.

Investors holding shares in physical or demat form can access the annual report and other statutory filings linked to this AGM through the company’s investor relations portal. The seamless digital execution of the AGM underscores the firm's adoption of modern technological tools for corporate administration.